SEC Filing Summary: TNF Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.) on July 26, 2024, covering events occurring on July 22, 2024. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and administrative changes rather than financial performance.
Material Changes
- Corporate Name Change: Effective July 22, 2024, the Company changed its name from "MyMD Pharmaceuticals, Inc." to "TNF Pharmaceuticals, Inc."
- Trading Symbol Change: Effective before market open on July 24, 2024, the common stock ticker symbol changed from "MYMD" to "TNFA" on the Nasdaq Stock Market.
- Security Holder Rights: The name change does not affect the rights of security holders, and there is no change to the Company's CUSIP number.
- Approval Status: Stockholder approval was not required for these changes under Section 242 of the Delaware General Corporation Law.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors related to operations. The document notes that press releases regarding the name and symbol changes are furnished as exhibits but are not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the new ticker symbol "TNFA" on trading platforms effective July 24, 2024.
- Confirm that the CUSIP number remains unchanged despite the corporate name change.
- Review the Certificate of Amendment (Exhibit 3.1) for any additional bylaw modifications not summarized in the main text.
- Check subsequent filings for the first financial report issued under the new corporate name.